Absorption of omadacycline is impaired by antacids containing aluminum.
Source: NLP:omadacycline
Brand names: Nuzyra
Tetracycline-class Antibacterial
Route: Intravenous, Oral
Contraindications
4 CONTRAINDICATIONS NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients [see Warnings and Precautions (5.3) and Adverse Reactions (6.1) ]. Known hypersensitivity to omadacycline, tetracycline class antibacterial drugs or any of the excipients in NUZYRA ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary NUZYRA, like other tetracycline class antibacterial drugs, may cause discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimester of pregnancy [see Warnings and Precautions (5.2 , 5.3) , Data , Use in Specific Populations (8.4) ]. The limited available data of NUZYRA use in pregnant women is insufficient to inform drug associated risk of major birth defects and miscarriages. Animal studies indicate that administration of omadacycline during the period of organogenesis resulted in fetal loss and/or congenital malformations in pregnant rats and rabbits at 7 times and 3 times the mean AUC exposure, respectively, of the clinical intravenous dose of 100 mg and the oral dose of 300 mg. Reductions in fetal weight occurred in rats at all administered doses (see Data ). In a fertility study, administration to rats during mating and early pregnancy resulted in embryo loss at 20 mg/kg/day; systemic exposure based on AUC was approximately equal to the clinical exposure level [see Nonclinical Toxicology (13.1) ] . Results of studies in rats with omadacycline have shown tooth discoloration. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15-20%. Data Animal Data Intravenous infusion of omadacycline to pregnant rats during organogenesis (gestation days 6-17) at doses of 5 to 80 mg/kg/day resulted in maternal lethality at 80 mg/kg/day. Increased embryo-fetal lethality and fetal malformations (whole body edema) occurred at 60 mg/kg/day (7 times the clinical AUC), dose-dependent reductions in fetal body weight occurred at all doses, and delayed skeletal ossification occurred at doses as low
6 interactions on record
Absorption of omadacycline is impaired by antacids containing aluminum.
Source: NLP:omadacycline
Absorption of omadacycline is impaired by antacids containing calcium.
Source: NLP:omadacycline
Absorption of omadacycline is impaired by antacids containing magnesium.
Source: NLP:omadacycline
Absorption of omadacycline is impaired by bismuth subsalicylate.
Source: NLP:omadacycline
Absorption of omadacycline is impaired by iron containing preparations.
Source: NLP:omadacycline
Tetracyclines depress plasma prothrombin activity; patients may require downward adjustment of anticoagulant dosage.
Source: NLP:omadacycline